Aura Biosciences (AURA) Stock Price, News & Analysis

Company Overview

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area.

Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

Aura is also exploring its technology for other ocular and solid tumors. Its programs remain under clinical development, and belzupacap sarotalocan is not an approved treatment.

Key Stats

• Today's Range: $7.31 to $7.72
• 50-Day Range: $6.00 to $7.66
• 52-Week Range: $4.73 to $9.53
• Volume: 648,447 shs
• Average Volume: 809,336 shs
• Market Capitalization: $791.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Moderate Buy

Aura Biosciences Stock Analysis - MarketRank™

Aura Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 615th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aura Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aura Biosciences has a consensus price target of $17.50, representing about 130.0% upside from its current price of $7.61.

Amount of Analyst Coverage

Aura Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aura Biosciences are expected to grow in the coming year, from ($1.50) to ($1.19) per share.

Price to Book Value per Share Ratio

Aura Biosciences has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.29% of the float of Aura Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aura Biosciences has a short interest ratio ("days to cover") of 13.67, which indicates bearish sentiment.

Change versus previous month

Short interest in Aura Biosciences has recently decreased by 3.87%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aura Biosciences does not currently pay a dividend.

Dividend Growth

Aura Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Aura Biosciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Aura Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aura Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.90% of the stock of Aura Biosciences is held by insiders.

Percentage Held by Institutions

96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AURA
• CIK: 1501796
• Web: www.aurabiosciences.com
• Phone: 617-500-8864
• Fax: N/A
• Employees: 113
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Aura Biosciences: $17.50
• High Price Target: $18.00
• Low Price Target: $17.00
• Potential Upside/Downside: +130.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$106.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.68%
• Return on Assets: -56.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.20
• Quick Ratio: 16.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.76 per share
• Price / Book: 2.76

Miscellaneous

• Outstanding Shares: 104,070,000
• Free Float: 101,735,000
• Market Cap: $791.97 million
• Optionable: Optionable
• Beta: 0.41